Table of Content


Introduction
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Indications, 2021 (Contd..3)
Number of Products under Development by Indications, 2021 (Contd..4)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Companies, 2021 (Contd..7)
Products under Development by Companies, 2021 (Contd..8)
Products under Development by Companies, 2021 (Contd..9)
Products under Development by Companies, 2021 (Contd..10)
Products under Development by Companies, 2021 (Contd..11)
Products under Development by Companies, 2021 (Contd..12)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Abbisko Therapeutics Co Ltd, 2021
Pipeline by Akero Therapeutics Inc, 2021
Pipeline by Astellas Pharma Inc, 2021
Pipeline by Bayer AG, 2021
Pipeline by Betta Pharmaceuticals Co Ltd, 2021
Pipeline by BioArdis LLC, 2021
Pipeline by Blueprint Medicines Corp, 2021
Pipeline by Eddingpharm Inc, 2021
Pipeline by Eisai Co Ltd, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by EUSOL Biotech Co Ltd, 2021
Pipeline by Everest Medicines Ltd, 2021
Pipeline by Genosco Inc, 2021
Pipeline by H3 Biomedicine Inc, 2021
Pipeline by ImmunoForge Co Ltd, 2021
Pipeline by InnoCare Pharma Ltd, 2021
Pipeline by Johnson & Johnson, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by NGM Biopharmaceuticals Inc, 2021
Pipeline by QED Therapeutics Inc, 2021
Pipeline by Vichem Chemie Research Ltd, 2021
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021